Prokidney Corp (PROK)

$2.45

+0.05

(+2.08%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.39
    $2.50
    $2.45
    downward going graph

    2.65%

    Downside

    Day's Volatility :4.6%

    Upside

    2.0%

    downward going graph
  • $1.12
    $13.51
    $2.45
    downward going graph

    54.29%

    Downside

    52 Weeks Volatility :91.71%

    Upside

    81.87%

    downward going graph

Returns

PeriodProkidney CorpIndex (Russel 2000)
3 Months
13.21%
0.0%
6 Months
69.01%
0.0%
1 Year
-79.4%
0.0%
3 Years
-75.66%
-20.2%

Highlights

Market Capitalization
1.8B
Book Value
- $17.79
Earnings Per Share (EPS)
-0.57
Wall Street Target Price
4.83
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.34%
Return On Equity TTM
-31.72%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-146.6M
Diluted Eps TTM
-0.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.97
EPS Estimate Next Year
-0.68
EPS Estimate Current Quarter
-0.18
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Prokidney Corp(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 97.14%

Current $2.45
Target $4.83

Technicals Summary

Sell

Neutral

Buy

Prokidney Corp is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prokidney Corp
Prokidney Corp
5.73%
69.01%
-79.4%
-75.66%
-75.93%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prokidney Corp
Prokidney Corp
NA
NA
NA
-0.97
-0.32
-0.21
NA
-17.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prokidney Corp
Prokidney Corp
Buy
$1.8B
-75.93%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Prokidney Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 141.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 262.2%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    8.95%

  • Suvretta Capital Management, LLC

    3.35%

  • BlackRock Inc

    2.37%

  • Bleichroeder LP

    1.73%

  • Vanguard Group Inc

    1.57%

  • Brown University

    0.87%

Company Information

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.

Organization
Prokidney Corp
Employees
163
CEO
Dr. Timothy A. Bertram D.V.M., Ph.D.
Industry
Financial

Discover More

FAQs